Group items tagged

The Pharmaceutical Services Negotiating Committee (PSNC) has launched Pharmacy Pressures Survey 2023 to make case against the 'unprecedented financial and operational challenges' faced by the community pharmacies in England. The Committee has urged those working in or owns a community pharmacy to 'take part' in the survey. "The survey results will be critical to help us to show Government and the NHS how difficult things now are for pharmacies, and to persuade them to take action. We will be using the results in our negotiations, in our conversations with MPs, Ministers and in national media work as part of the joint #saveourpharmacies campaign," said PSNC. The Pharmacy Pressures Survey is once again comprised of two surveys to give insight into both financial and operational pressures. Together with the other national pharmacy organisations PSNC are working both to show policy makers the severity of the problems and to lobby for Government and NHS action to ease the pressures.

The Association of the British Pharmaceutical Industry (ABPI) on Thursday (February 2) called for the government to scrap its plans to raise the repayment rates for drugmakers, to avoid possible setbacks in the sector. Drugmakers that are part of the government's voluntary scheme agreement, which makes branded medicines affordable for people, are required to pay a part of their drug revenue to the government. The Department of Health and Social Care plans to raise the revenue clawback rate to 27.5 per cent from 24.5 per cent. The country's ongoing attempt to raise rates is likely to send the "worst possible signal" to global investors and boardrooms, said the ABPI. "Hiking these clawbacks to such uncompetitive levels risks undermining the UK's offer to global life sciences companies," Richard Torbett, chief executive of the ABPI, said in a statement. Pharmaceuticals giants AbbVie and Eli Lilly withdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5 per cent.

The Pharmaceutical Services Negotiating Committee (PSNC) has appointed Robbie Turner as chief transformation officer, to work closely with LPCs as part of its newly launched Transforming Pharmacy Representation (TAPR) programme. PSNC launched the TAPR Programme in response to the contractor vote in favour of the Review Steering Group's proposals. As part of the programme - alongside actioning the recommendations for PSNC - there will be support for LPCs to implement their proposals. Williams will be responsible for leading, driving, and having oversight of the TAPR workstream to increase efficiency and outcomes across the network of LPCs in England. This will include the provision of specialist hands-on guidance and support to LPC members and officers, to promote implementation of the RSG proposals, best practice and challenging the status quo. Williams was formerly chief officer of Community Pharmacy West Yorkshire LPC and subsequently Director for England and Director of Pharmacy and Member Experience at the Royal Pharmaceutical Society.

The Pharmaceutical Defence Association (PDA) has urged health ministers of the UK to take a strict and necessary action against the unnecessary closures of pharmacy. Concerned over the rising number of pharmacy closures, PDA has written an open letter to health secretary Steve Barclay; Robin Swann, health minister for Northern Ireland; Eluned Morgan, minister of health and social services for Wales; and Humza Yousaf, the Scottish health secretary. In its letter, PDA said: "The minister of health must now ensure the regulation of poor business behaviours and be prepared to take over rogue pharmacies, however large their corporate owner may be. If patients' access to NHS services is to be protected from the consequences of avoidable full or part-day pharmacy closures." The association believes it is only a matter of time before serious harm to patients' health will be caused by the decisions of mainly large chains of pharmacies to close some of their branches for all or part of a day, instead of engaging an available pharmacist to cover their agreed opening hours. "While a small number of unforeseen closures have always occurred from time to time in pharmacies for genuine reasons, the indiscriminate scale at which closures have now become commonplace seems to have evolved over the last 20 months."

Being accepted and appearing attractive has always been among the most coveted goals in the world, which has given rise to the multibillion-dollar cosmetic and beauty industry. Fairy stories have been written about everlasting charm, and battles have been waged over attaining beauty. For the most part throughout history, people have continuously sought ways to improve their features using natural materials, and as technology advanced, they began to use technical methods like light therapy to accomplish the same goal. Chains of cosmetic clinics have sprouted up as a result of advances in technology and cosmetic materials, providing a variety of techniques to slow down the aging process or improve our appearance. So how can you set up your own beauty treatment and plastic surgery clinic to take advantage of this rapidly expanding market? Here are some pieces of advice! FIND QUALITY EQUIPMENT Your success depends on securing the greatest tools available for skin care and plastic surgery. Good quality equipment is a complete solution for distinguishing yourself from the competition. The initial step would be to locate different vendors. Using criteria like the cost of the equipment and replacement parts, the vendor's training, the company's reputation, the after-sales services, yearly maintenance, system performance, warranty, and extended warranties, you may narrow down your list of recommended suppliers. When selecting the appropriate medical supplies and equipment for your clinic, keep your budget in mind.

The regulators have added 10 new products to the 'Drugs for which Discount is Not Deducted' (DND) list from Thursday (01 June). Community Pharmacy England on behalf of its members had made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in the inclusion of 10 new products in the DND. More than 610 products are granted DND status following checks made by Community Pharmacy England's dispensing & supply team over the past 3 years to ensure fair reimbursement for our members. The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II. "We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, on behalf of our members accordingly," said Community Pharmacy England.

The government has extended VAT exemption from Monday (1 May) on healthcare services carried out by pharmacy staff under the supervision of pharmacists. HM Revenue and Customs has issued a note detailing the change to the VAT treatment of medical services. The Government said this will bring the VAT treatment of pharmacists in line with other registered health professionals providing medical services to the public. The Pharmaceutical Services Negotiating Committee (PSNC) said: "This is something that PSNC has been seeking Government agreement on for a long time, including in recent CPCF negotiations." PSNC believes that the extension of this VAT exemption will help as community pharmacy businesses try to make better use of the skill mix in their teams both now and in the future. "Not only does it enable contractors to review the VAT status of any locally commissioned services currently provided by non-registered pharmacy staff but also, in time, it could be used to amend nationally commissioned services to allow support staff to provide certain parts. For example, following a recent amendment to the service Directions, pharmacy technicians are now able to perform blood pressure checks as part of the Hypertension Case-Finding Service and deliver the Smoking Cessation Service.

A group of pharmacists on Saturday (July 2) took part in this year's Pride in London parade, as the annual LGBTQ+ celebration returned to the capital after three years due to the Covid-19 pandemic. Those who participated in the march called on the government to ban conversion therapy for all LGBT+ people, reform the Gender Recognition Act, and provide equal protection for LGBT+ communities against hate crime. The event which drew a crowd of a million people marked the 50th anniversary since the first ever parade in London in 1972. Amandeep Doll, head of professional belonging at RPS, said: "It was a privilege to join in the recognition of the diversity of the LGBTQI+ community and our profession, especially on such a historic occasion. Our group of pharmacists and allies from all parts of the country loved the excitement and buzz of the day."

The General Pharmaceutical Council (GPhC) has developed two new resources- Keeping patients safe being open and honest and Pharmacy team toolkit - learning from incidents, to help pharmacists and pharmacy technicians fulfil the duty of candour - the professional responsibility to be open and honest with patients if/when something goes wrong. The new resources bring together relevant existing policy, standards, and previous statements on the professional obligations of pharmacists and pharmacy technicians, with respect to candour. It also emphasises that the duty of candour is not an add on - it's a fundamental part of pharmacy professional practice. The responsibility to be open and honest applies even in difficult or challenging times and it's essential that professionals do the right thing for patients, their families and carers. Saying sorry meaningfully when things go wrong is vital for everyone involved. Given the link with issues around liability and indemnity, the National Pharmacy Association and the Pharmacists' Defence Association - as leading providers of professional indemnity - have also contributed to the new resources and highlighted the importance of openness and transparency in this context.

Professional leadership bodies from around the world discussed workforce shortages in community pharmacy and other challenges affecting the sector at a global meeting held in Paris last month. Delegated from Denmark, Australia, Ireland, New Zealand, Portugal, Spain, US and the UK updated the conference on how the profession was progressing in practice, technology and workforce development in their respective countries. The UK was represented at World Pharmacy Council meeting by National Pharmacy Association chair Andrew Lane and chief executive at the Pharmaceutical Services Negotiating Committee Janet Morrison. Lane said: "It's very useful to be part of a global network of pharmacy bodies who are all going through similar challenges as we are in the UK. Sharing intelligence on other pharmacy systems around the world helps us to prepare the right strategy for engaging with the NHS at home. "Hearing some of the strides in services and digital technology in the profession gives us hope for the future of the sector. It's clear however that key challenges such as workforce shortages are starting to have an effect in other parts of the world too."

The Pharmacists' Defence Association (PDA) has launched a brutal attack on some large pharmacy chains for full or part-day closures of some of their shops throughout the UK. It published an Open Letter on Tuesday (July 19) demanding urgent action "to protect patients by ensuring that essential community pharmacy services are provided safely and consistently". PDA chair Mark Koizol, who wrote the letter, went on to allege that many of those closure were "being orchestrated". He wrote that the "pharmacist shortage" narrative cited as a reason for these closures was "very different" from "the reality experienced by our members", including both employed and locum pharmacists. "We have evidence to show that these closures are being announced up to four weeks in advance," Koizol claimed. He gave examples of how a large company attempted to reduce the pre-agreed rate of locums and where this was not accepted, the shift was cancelled, resulting in the pharmacy being closed for part or full day.

The General Pharmaceutical Council (GPhC) has committed to playing its part in addressing climate change by undertaking work to establish a carbon footprint baseline to improve its environmental performance. In a statement on Monday (July 18) the pharmacy regulator laid out what it called its vision "to have safe and effective pharmacy care at the heart of healthier communities". Stating that climate change creates health risks and exacerbates health inequalities, GPHC said: "We believe we all have a role to play in contributing to addressing climate change." It announced that it has just joined "a newly formed cross-regulatory group" formed to address issues such as "environmental sustainability". "At the GPhC we have brought together colleagues from across the organisation to consider the environmental impact we have as an employer and as a regulator," it declared.

All candidates in Great Britain who faced problems when sitting the General Pharmaceutical Council (GPhC)'s registration assessment will be eligible for provisional registration, the pharmacy regulator has announced. However, they are eligible only if they meet eligibility criteria set out in the GPhC policy which states: "Have sat the registration assessment on 29 June 2022 and experienced delays of 30 minutes or more in starting or completing either or both Part 1 and/or Part 2 of the registration assessment due to technical or other IT difficulties (This also includes those who withdrew from the registration assessment on the day due to the start of the assessment being delayed by 30 minutes or more)." GPhC added that these candidates will also be able to claim a full refund, and this sitting will not count as one of their three attempts. Gisela Abbam, chair of the GPhC, said: "We would like to sincerely apologise again to the candidates who experienced significant problems during their registration assessment sitting.

England's chief pharmaceutical officer David Webb on Friday (July 22) officially opened a community health hub at a Hindu temple in west London. The interactive health hub, which was built as part of the 'Festival of Inspiration' - a 10-day cultural celebration of the UK's South Asian Hindu communities, will provide visitors with free health awareness and well-being advice. The cultural extravaganza, which ends on July 31, draws upon the inspiring life, work and wisdom of His Holiness Pramukh Swami Maharaj, one of the world's great spiritual leaders and creator of the iconic Neasden Temple. Sharing his reflection on the festival and the health hub, Webb said: "It's been an absolute pleasure to visit and be a part of the Festival of Inspiration on the hundredth centenary of His Holiness. I've been really impressed by the extensive programme of engagement with the community to improve health and wellbeing." Senior pharmacist Prof Mahendra Patel accompanied Webb during the opening ceremony.

The Scottish government is planning to publish its review report on use of automated technology in community pharmacies by the end of 2023. The technology being trialled as part of the pilot includes robotic process automation, automated medicine storage systems, barcode scanners and prescription collection kiosks. The evaluation, which started prior to the COVID-19 pandemic, is due to be completed at the end of November 2023. Patricia Findlay, professor of work and employment relations at the University of Strathclyde, who was commissioned to produce the report, told The Pharmaceutical Journal that the pilot pharmacies taking part in the scheme are all based in Scotland, but she didn't reveal their names.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

Dr Bharat Shah CBE regrets that neither community pharmacists nor pharmaceutical wholesalers in the UK have any control over how Category M reimbursement prices in Part VIII A of the Drug Tariff are determined. The co-founder and chief executive of Sigma Pharmaceuticals was speaking at a conference organised by Avicenna in West London on Sunday (March 6). Introduced into the Drug Tariff in April 2005, Category M is used to set the reimbursement prices of over 500 drugs. The Department of Health and Social Care makes the final decision on the amount of reimbursement (cost of drugs and appliances supplied against an NHS prescription form) and remuneration (fees paid as part of the NHS community pharmacy contract for the provision of a service).

The Royal Pharmaceutical Society has opened a survey which asks its members how they would want to take part in and learn about decisions made by the RPS. The RPS said the survey was a core part of the independent review of member participation and communications led by communications consultancy Luther Pendragon. It said: "We will be asking our members to join focus groups to give their opinions on how participation can be developed and strengthened, and how RPS communications about decisions it has taken on behalf of the profession through its governance boards can be improved. We will also be asking our elected members and key external stakeholders for their views over the coming weeks." The Luther team will then build a series of recommendations for RPS and develop a corporate communications strategy which will include action plans to enable greater participation. RPS president Claire Anderson said: "We want to hear from as many of you as possible through our survey to inform how the organisation works with and engages with you, our members.

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.

Representatives from the national community pharmacy bodies will brief the MPs on the severe challenges facing community pharmacies on Tuesday (21 March) at a roundtable summit. The roundtable summit will include discussions on the urgent action needed to address the current severe challenges being faced by community pharmacy, as well as the sector's role in the upcoming Primary Care Recovery Plan, said PSNC. The Parliamentary event this week has been coordinated by PSNC as part of the joint #SaveOurPharmacies campaign which exceeded 30,000 signatories in a week. The Association of Independent Pharmacies (AIM), the Company Chemists' Association (CCA), the National Pharmacy Association (NPA) and PSNC will take part at the event. A spokesperson for the #SaveOurPharmacies campaign group said: "30,000 signatures in a week indicates a high level of underlying public support for community pharmacy and it's a good start to the #SaveOurPharmacies campaign. A petition by itself won't change the world, but it works as a kind of drumbeat for the campaign, giving forward momentum, and it's a really easy way to express your opinion. We hope the new window poster - along with all the resources available at saveourpharmacies.co.uk - will help as many pharmacies as possible to drum up support from their patients, and we're really grateful to Communications International Group for helping us to print and distribute this.